Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q3

3151.TEDINET S100Q4CC
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥443.2bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥439.3bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥1.9bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥2.1bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥4.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.2bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥4.1bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥2.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥336.1bnat 2022-12-31Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥346.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥233.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥102.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥101.3bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥35.2bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥46.592022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.222022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.842021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.252021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥236m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥126m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-12-31¥426.2bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-12-31¥418.3bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥6m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥77m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥276m
—segment totalrevenue2022-04-01 → 2022-12-31¥448.2bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥440.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥453.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥443.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥1.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥4.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥2.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31−¥119m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31¥36m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2021-04-01 → 2021-12-31¥421.5bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2021-04-01 → 2021-12-31¥414.9bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥6.6bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥162m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥7.8bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥7.8bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥318m
—segment totalrevenue2021-04-01 → 2021-12-31¥443.1bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥436.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥6.6bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥447.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥439.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 374
ItemContextValueUnit
Selling general and administrative expensesPrior1YTDDuration30208000000JPY
Selling general and administrative expensesCurrentYTDDuration31977000000JPY
Operating incomePrior1YTDDuration2086000000JPY
Operating incomeCurrentYTDDuration1866000000JPY
Interest income noiPrior1YTDDuration37000000JPY
Interest income noiCurrentYTDDuration51000000JPY
Dividends income noiPrior1YTDDuration578000000JPY
Dividends income noiCurrentYTDDuration555000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration49000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration83000000JPY
Office work fee noiPrior1YTDDuration1180000000JPY
Office work fee noiCurrentYTDDuration1194000000JPY
Other noiPrior1YTDDuration453000000JPY
Other noiCurrentYTDDuration695000000JPY
Non operating incomePrior1YTDDuration2298000000JPY
Non operating incomeCurrentYTDDuration2580000000JPY
Interest expenses noePrior1YTDDuration74000000JPY
Interest expenses noeCurrentYTDDuration74000000JPY
Rent expenses noePrior1YTDDuration64000000JPY
Rent expenses noeCurrentYTDDuration60000000JPY
Other noePrior1YTDDuration25000000JPY
Other noeCurrentYTDDuration9000000JPY
Non operating expensesPrior1YTDDuration164000000JPY
Non operating expensesCurrentYTDDuration144000000JPY
Ordinary incomePrior1YTDDuration4220000000JPY
Ordinary incomeCurrentYTDDuration4302000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration12000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration15000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration59000000JPY
Other eiPrior1YTDDuration5000000JPY
Other eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration17000000JPY
Extraordinary incomeCurrentYTDDuration74000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration19000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration0JPY
Impairment loss elPrior1YTDDuration47000000JPY
Impairment loss elCurrentYTDDuration22000000JPY
Loss on valuation of investment securities elPrior1YTDDuration8000000JPY
Loss on valuation of investment securities elCurrentYTDDuration56000000JPY
Soil removal expenses elPrior1YTDDuration－JPY
Soil removal expenses elCurrentYTDDuration136000000JPY
Other elPrior1YTDDuration16000000JPY
Other elCurrentYTDDuration28000000JPY
Extraordinary lossPrior1YTDDuration92000000JPY
Extraordinary lossCurrentYTDDuration244000000JPY
Income before income taxesPrior1YTDDuration4145000000JPY
Income before income taxesCurrentYTDDuration4132000000JPY
Income taxesPrior1YTDDuration1608000000JPY
Income taxesCurrentYTDDuration1622000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass